Skip to main content
SpringerLink
Log in

The insulin resistance syndrome

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Insulin-mediated glucose disposal varies widely in apparently healthy human beings. When insulin-resistant individuals cannot secrete enough insulin to overcome this defect, type 2 diabetes occurs. However, the ability of hyperinsulinemia to prevent gross decompensation of glucose tolerance is a mixed blessing, and insulin-resistant/hyperinsulinemic individuals are more likely to be somewhat glucose intolerant, hypertensive, and have a high plasma triglyceride and low high-density lipoprotein cholesterol concentration. These changes increase the risk of cardiovascular disease, and in 1988 these relationships were explicitly addressed and designated as comprising a Syndrome X. The fact that insulin resistance and its consequences are important cardiovascular risk factors has become widely recognized, and the importance of this syndrome was acknowledged in the report of the Adult Treatment Panel III. There has been a rapid increase in the abnormalities associated with insulin resistance/compensatory hyperinsulinemia in the 15 years since the notion of Syndrome X was introduced, and there are now almost as many components as there are names that have been given to this cluster of abnormalities. Because there is a large body of evidence that the basic abnormality leading to all of these changes is resistance to insulin-mediated glucose disposal, it seems reasonable to suggest that the cluster of abnormalities related to the defect in insulin action be designated as the Insulin Resistance Syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM: Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000, 23:171–175.

    Article  PubMed  CAS  Google Scholar 

  2. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  3. Reaven GM: Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease: syndrome X. In Medical Management of Diabetes and Heart Disease. Edited by Sobell BE, Schneider DJ: New York: Mercel Dekker; 2002:117–136.

    Google Scholar 

  4. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2002, 285:2846–2497.

  5. Fuller JF, Shipley MJ, Rose G, et al.: Coronary-heart disease and impaired glucose tolerance: the Whitehall Study. Lancet 1980, 1:1373–1376.

    PubMed  CAS  Google Scholar 

  6. Lillioja S, Mott DM, Spraul M, et al.: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. N Engl J Med 1993, 329:1988–1992.

    Article  PubMed  CAS  Google Scholar 

  7. Facchini F, Chen YD, Hollenbeck C, Reaven GM: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991, 266:3008–3011.

    Article  PubMed  CAS  Google Scholar 

  8. Laws A, Reaven GM: Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Int Med 1992, 231:25–30.

    Article  CAS  Google Scholar 

  9. Castelli WP, Garrison RJ, Wilson PW, et al.: Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986, 256:2385–2387.

    Article  Google Scholar 

  10. Austin MA, Hokanson JE, Edwards KI: Hypertriglycridemia as a cardiovascular risk factor. Am J Cardiol 1998, 81:7B-12B.

    Article  PubMed  CAS  Google Scholar 

  11. Reaven GM, Chen YD, Jeppesen J, et al.: Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993, 92:141–146.

    PubMed  CAS  Google Scholar 

  12. Austin MA, Breslow JL, Hennekens CH, et al.: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917–1921.

    Article  PubMed  CAS  Google Scholar 

  13. Jeppesen J., Hollenbeck CB, Zhou MY, et al.: Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995, 15:320–324.

    PubMed  CAS  Google Scholar 

  14. Patsch JR, Miesenbock T, Hopferwieser T, et al.: Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992, 12:1336–1345.

    PubMed  CAS  Google Scholar 

  15. Facchini FS, Riccardo A, Stoohs A, Reaven GM: Enhanced sympathetic nervous system activity-the linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens 1996, 9:1013–1017.

    Article  PubMed  CAS  Google Scholar 

  16. DeFronzo RA, Cooke C, Andres R, et al.: The effect of insulin in renal handling of sodium, potassium, calcium and phosphate in man. J Clin Invest 1975, 55:845–855.

    PubMed  CAS  Google Scholar 

  17. Zavaroni I, Mazza S, Dall’Aglio E: Prevalence of hyperinsulinaemia in patients with high blood pressure. J Int Med 1992, 231:1128–1130.

    Google Scholar 

  18. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: High triglycrides nd low HDL cholersterol and blood pressure and risk of ischemic heart disease. Hypertension 2000, 36:226–232.

    PubMed  CAS  Google Scholar 

  19. Juhan-Vague I, Thompson SG, Jeppesen J, on behalf of the ECAT Angina Pectoris Study Group: Involvement of the hemostatic system in the insulin resistance syndrome. Arterioscler Thromb 1993, 13:1865–1873.

    PubMed  CAS  Google Scholar 

  20. Meigs JB, Mittelmann MA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. JAMA 2000, 283:221–228.

    Article  PubMed  CAS  Google Scholar 

  21. Chen NG, Abbasi F, Lamendola C, et al.: Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers. Circulation 1999, 100:940–943.

    PubMed  CAS  Google Scholar 

  22. Chen NG, Holmes M, Reaven GM: Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999, 84:3485–3489.

    Article  PubMed  CAS  Google Scholar 

  23. Stuhlinger MC, Abbasi F, Chu JW, et al.: Relationship between insulin resistance and an endogenous nitiric oxide synthase inhibitor. JAMA 2002, 287:1420–1426.

    Article  PubMed  Google Scholar 

  24. Baron A: Vascular reactivity. Am J Cardiol 1999, 84:25J-27J.

    Article  PubMed  CAS  Google Scholar 

  25. Dunaiff A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774–800.

    Article  Google Scholar 

  26. Sanyal AJ, Campbell-Sargent C, Mirashi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183–1192.

    Article  PubMed  CAS  Google Scholar 

  27. Argiles JM, Lopez-Soriano R: Insulin and cancer. Int J Oncol 2001, 18:683–687.

    PubMed  CAS  Google Scholar 

  28. Jeppesen J, Hein HO, Dsuadicani P, et al.: Low triglycerides-high high density lipoprotein cholesterol and risk of ischemic heart disease. Arch Int Med 2001, 161:361–366.

    Article  CAS  Google Scholar 

  29. Warram JH, Martin BC, Krowlewski AS, et al.: Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the off-spring of the diabetic parents. Ann Intern Med 1990, 113:909.

    PubMed  CAS  Google Scholar 

  30. Facchini F, Chen YD, Clinkingbeard C, et al.: Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens 1992, 5:694–699.

    PubMed  CAS  Google Scholar 

  31. Lillioja S, Mott DM, Zawadzki JK, et al.: In vivo insulin action is a familial characteristic in nondiabetic Pima Indians. Diabetes 1987, 36:1329–1335.

    Article  PubMed  CAS  Google Scholar 

  32. Couston DR, Carpenter MW, O’Sullivan PS, Carr SR: Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol 1993, 168:1139–1145.

    Google Scholar 

  33. Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America, edn 2. Bethesda, MD: NIH, NIDDK; 1995:429–448.

    Google Scholar 

  34. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002, 25(suppl 1):S5–S20.

  35. Bogardus C, Lillioja S, Mott DM, et al.: Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985, 248:E286-E291.

    PubMed  CAS  Google Scholar 

  36. Olefsky JM, Reaven GM, Farquhar JW: Effects of weight reduction on obesity: studies of carbohydrate and lipid metabolism. J Clin Invest 1974, 53:64–76.

    Article  PubMed  CAS  Google Scholar 

  37. Ferrannini E, Natali A, Bell P, et al., on behalf of the European Group for the Study of Insulin Resistance. Insulin resistance and hypersecretion in Obesity. J Clin Invest 1997, 100:1166–1173.

    PubMed  CAS  Google Scholar 

  38. McLaughlin T, Abbasi F, Kim HS, et al.: Relationship between insulin resistance, weight loss, and coronary heart disease in healthy, obese women. Metabolism 2001, 7:795–800.

    Article  Google Scholar 

  39. Abbasi F, Brown BW, Lamendola C, et al.: Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002, 40:937–943.

    Article  PubMed  CAS  Google Scholar 

  40. McLaughlin T, Abbasi F, Lamendola C, et al.: Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002, 106:2908–2912.

    Article  PubMed  CAS  Google Scholar 

  41. McKeigue PM: Ethnic variations in insulin resistance and glucose tolerance. In Insulin Resistance: The Metabolic Syndrome X. Totowa, NJ: Humana Press; 1999:19–34.

    Google Scholar 

  42. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161:397–404.

    Article  Google Scholar 

  43. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773–2776.

    Article  PubMed  CAS  Google Scholar 

  44. Facchini FS, Hua N, Abbasi F, Reaven GM: Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001, 86:3574–3578.

    Article  PubMed  CAS  Google Scholar 

  45. Tuomilehto J, Lindstrom J, Eriksson JG, et al.: Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  46. Knowler WC, Barrett-Connor E, Fowler SE, et al., for the Diabetes Prevention Program Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  PubMed  CAS  Google Scholar 

  47. Golay A, Allaz AF, Morel Y, et al.: Similar weight loss with low-or high-carbohydrate diets. Am J Clin Nutr 1996, 63:174–178.

    PubMed  CAS  Google Scholar 

  48. Nestler JE, Jakuboficz J, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998, 338:1876–1880.

    Article  PubMed  CAS  Google Scholar 

  49. Hollenbeck CB, Johnston P, Varasteh BB, et al.: Effects of metformin on glucose insulin and lipid metabolism in patients with mild hypertryglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabetes Metab 1991, 17:483–485.

    CAS  Google Scholar 

  50. Reaven GM, Segal K, Hauptman J, et al.: Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001, 87:827–831.

    Article  PubMed  CAS  Google Scholar 

  51. Reaven GM: Do high carbohydrate diets prevent the development or attenuate the manifestations (or both) of syndrome X? A viewpoint strongly against. Cur Opin Lipidol 1997, 8:23–27.

    Article  CAS  Google Scholar 

  52. Mensink RP, Katan MB: Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb 1992, 12:911–919.

    PubMed  CAS  Google Scholar 

  53. Gardner CD, Kraemer HC: Monounsaturated versus polyunsaturated dietary fat and serum lipids-meta analysis. Arterioscler Thromb Vasc Biol 1995, 15:1917–1927.

    PubMed  CAS  Google Scholar 

  54. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002, 25(suppl 1):S33–S49.

Download references

Author information

Authors and Affiliations

  1. Falk CVRC, Stanford Medical Center, 300 Pasteur Drive, 94305, Stanford, CA, USA

    Gerald M. Reaven MD

Authors
  1. Gerald M. Reaven MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reaven, G.M. The insulin resistance syndrome. Curr Atheroscler Rep 5, 364–371 (2003). https://doi.org/10.1007/s11883-003-0007-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-003-0007-0

Keywords

Search

Navigation